Northwell Direct to Provide Telehealth Services to U.S. Department of State

Northwell Direct today announced that it has been selected as the subcontractor on a U.S. Department of State (DOS) contract to provide telehealth consult services to DOS medical providers serving U.S. Government (USG) employees and family members posted overseas.

Leveraging Northwell Health’s extensive network of specialists, Northwell Direct will provide consultation services to DOS that will assist its medical staff around the world. DOS providers can request consultations 24 hours a day, 365 days a year that will be triaged and navigated to the appropriate Northwell specialty provider.

“Telemedicine is a unique area of opportunity for Northwell Direct to provide support and expertise to the Department of State,” said Jonathan Berkowitz, MD, medical director of center emergency medical services at Northwell Health. “We are virtually leveraging the collective expertise of our health system in innovative ways. The breadth and depth of services we have across our network, coupled with our advanced telehealth and integrated technology platform, allows us toextend our reach and impact far beyond the traditional borders of the health system and appropriately support the Department of State.”

Additionally, Northwell specialists will also provide support for pre-deployment medical clearances and clinical case reviews.

“Northwell Direct is proud to be working with the United States Department of State and doing our part to ensure that the employees and family members who serve our country have access to the highest quality health care services while serving abroad,” said Nick Stefanizzi, Chief Executive Officer of Northwell Direct. “The broad range of services we have deployed to meet the unique needs of the DOS are representative of the wholistic approach Northwell Direct takes to supportall of its employer clients both domestically and internationally.”

More than 100 specialties across medical, surgical, psychiatry and pediatrics will be made available to DOS providers, with the most consulted specialties including orthopedics, cardiology, radiology, neurosciences, dermatology, and emergency medicine.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”